Global Weight-Loss Devices Market is segmented By Type (Gastric band, Gastric balloon system, Electrical stimulation system, Gastric emptying system, Others), By Application (Hospitals, Clinics, Household, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Weight-Loss Devices Market The size is expected to grow at a high CAGR during the forecast period (2024-2031).
Devices which aid weight-loss are intended to help the patients lose their weight. Typically,with the help of weight-loss devices 50 percent of patients lose at least 5 percent of their initial body weight.
Market Scope
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Market Growth and Trends
The increasing prevalence of obesity and technological advancements in the healthcare system will drive the forecast period.
The increasing prevalence of obesity will drive the weight-loss devices market
The most important public health problems faced by the world today is the epidemic of obesity. Globally, adult obesity is common than under-nutrition.
According to the World Health Organisation, there are approximately 2 billion adults overweight. Of those, around 650 million are considered to be obese (BMI ≥30 kg/m²). Which equates to 39% (39% of men and 40% of women) of adults aged 18 or over who were overweight, with 13% obese. If the trend continues by 2025, it is estimated that 2.7 billion adults will be overweight, over 1 billion affected by obesity, and 177 million adults will be affected.
Therapies for weight loss or weight management start from healthy eating,exercise, prescription medicine,use of medical devices, and surgery. Typically healthy eating and exercise are recommended to help a person who is overweight lose excess weight. In recent times, there are four types of FDA-regulated devices intended for weight loss.
Technological advancements in the healthcare system will drive the market in the forecast period
The growing obesity epidemic has resulted in the need to create new, less invasive treatments, with a wider margin of safety and effectiveness for conditioning weight loss, at least more significant than the result obtained from treatment based on exercise and diet. Emerging new therapies include devices that are endoscopically placed and removed, classified as space-occupying devices, endoluminal bypass, restrictive or anatomic-remodeling procedures, and duodenal mucosal resurfacing.
In April 2019, the U.S. FDA authorized marketing for Plenity, a new weight management device to help overweight or obese adults. It is the first FDA approved weight loss product for people with a body mass index (BMI) of 25 or greater whereas other therapies can only be prescribed for people with a BMI of 30 or higher.
High cost and lack of awareness of the devices will hamper the weight-loss devices market
The weight-loss devices include gastric band devices, gastric space-occupying devices, and gastric emptying devices. The weight-management devices include oral removable palatal space-occupying devices and ingested transient gastric space-occupying devices. The effectiveness, safety, and cost of anti-obesity medical devices vary considerably by the type of medical device.
Health professionals and physicians have a unique opportunity to raise awareness of their weight status and its associated health risks in obese patients' and offer advice on weight management. Doctors are recommended to screen for obesity in the USA and refer all obese patients for weight loss treatment. Despite these recommendations, the current figures indicate that only a minority of health professionals routinely give weight advice. A range of barriers, including lack of time, lack of training or confidence, inadequate knowledge and teaching materials which are inadequate, have been identified as contributing to the relatively low rates of weight control advice from health professionals.
COVID-19 Impact Analysis
After facing disruption in the supply chain due to the Covid-19, induced lockdown, the weight-loss devices market is shaping its strategies to bank on rising in-home use and consumers' enhanced focus on health and wellness. The weight-loss devices segment relies on manufacturing and regulatory approvals for sales, which have been severely impacted due to the pandemic.
Market Segment Analysis
The gastric balloon system segment will dominate the weight-loss devices market
A weight-loss procedure called intragastric balloon placement involves placing a saline-filled silicone balloon in the stomach. This procedure helps to lose weight by limiting how much one can eat and making one feel fuller faster.The gastric balloons are designed to remain temporarily in the stomach for a period ranging from 16 weeks up to 12 months. Endoscopically placed balloons are then deflated and removed by way of another endoscopy. The 'procedure less balloon is designed to self-deflate and is then passed naturally into the toilet. Gastric balloons effectively reduce appetite and improve the feel of fullness (or satiety) after eating. They are regarded as effective training wheels – they are temporary devices to help kick start weight loss and institute long-lasting dietary and lifestyle changes. The intragastric balloon is more effective when combined with a comprehensive lifestyle program delivered by the doctor and specialist dietitian, behavioral and exercise professionals.
The new ORBERA™, FDA-approved Managed Weight Loss System showed that within six months the average person lost 3.1 times the weight compared with diet and exercise alone. With over 220,000 balloons distributed in over 80 countries, ORBERA™ is documenting positive results.
The hospitals segment will dominate the market
Obesity is a major drive in the development of diabetes and cardiovascular disease. Weight reduction and maintenance are key therapeutic goals in managing obesity and its associated comorbidities, type 2 diabetes in particular. The ultimate goal in developing medical devices for obesity is to create a semi-permanent or permanent intervention associated with little or no side effects. To provide a long-term solution for the treatment of obese patients the procedures need to be easy and safe to perform with the efficacy of the device maintained for long treatment periods. Most of these therapies described are in their investigational stages still and at present, are not likely to displace bariatric surgery in the treatment algorithm of obesity. It requires proper guidance and care, which is available in hospitals. To promote initial weight loss in patients before them undergoing elective surgery to reduce their intraoperative risk these devices may be used as an adjunct to surgery. Hospitals provide the best medical practitioner and advanced medical devices for weight loss. Hence, this segment will dominate the market.
Market Geographical Share
North America region will dominate the weight-loss devices market
Approximately two out of three U.S. adults are obese or overweight (69%), and one out of three is obese (36%). NHANES show that 39.6% of adults, 18.5 % of children ages 2 to 19 in America have obesity. The State of Obesity report noted that "these are the highest rates ever documented by NHANES. Approximately 70% of American adults are obese or overweight. Being obese or overweight is a serious health issue associated with some leading causes of death, including heart disease, stroke, diabetes, and it is also linked with an increased risk of a specific type of cancer.
Allurion Technologies, an established leader in developing proven, innovative and trusted weight loss experiences, announced the flagship Elipse gastric balloon by submission of Premarket Approval (PMA). Previously it had announced the successful completion of its landmark FDA pivotal study and the hiring of key personnel who will be leading the US market launch. For the eventual entry into the US market, the company has laid the foundation of these mildstones.
Market Companies
Some key players in the weight-loss devices market are ReShape Lifesciences, Inc, Helioscopie Medical Implants, Allurion, Spatz FGIA, Obalon Therapeutics, Inc, Medsil, Endalis, Silimed, Ethicon, Inc, Millenium Surgical Corporation, Zhengzhou YKinspection Enterprise Co., Ltd., Chongqing Xishan Science & Technology Co., Ltd, Guangzhou Lety Medical Limited
Weight-Loss Devices Market Key Companies to Watch
ReShape Lifesciences, Inc
Overview: ReShape Lifesciences Inc. is America's premier weight-loss and metabolic health solutions company, offering an integrated approach to managing and treating obesity.
The FDA-approved Lap-Band® program for weight loss is an alternative to more invasive surgical stapling procedure such as gastric bypass or sleeve gastrectomy that provides minimally invasive, long-term treatment of obesity. The ReShape Vest™ System is an investigational minimal invasive medical device, laparoscopically implanted that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps with rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The recently launched 𝗋𝖾𝗌𝗁𝖺𝗉𝖾𝗰𝗮𝗿𝗲™ virtual health coaching program is a reimbursed, virtual telehealth, weight-management program that supports lifestyles changes for all weight-loss patients to help them keep the weight off over time.
Product Portfolio: The company comprises Medical Devices, Minimally Invasive, Obesity, Metabolic Diseases, Gastrointestinal Disorders, Weight Loss, Bariatric Surgery, Gastric Vest System, Weight Management, Virtual Health Coaching, Virtual Weight Management, and Weight loss Surgery.
Key Development: On January 20, 2021, ReShape Lifesciences Inc., a global weight-loss solutions leader, announced that it has entered into a definitive merger agreement with Obalon Therapeutics, Inc., which is listed on the NASDAQ Capital Market, a company focused on developing and commercializing novel technologies for weight loss, under which ReShape and Obalon will combine in an all-stock transaction.
Why Purchase the Report?
- Visualize the composition of the weight-loss devices market segmentation By Type and applications highlighting the key commercial assets and players.
- Identify commercial opportunities in weight-loss devices market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of weight-loss devices market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The weight-loss devices market report would provide an access to an approx. 53 market data table, 45 figures and 200 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
